Shoji, S <br/><br/>
Myristoylated src-oncogene products are potently detected by the monoclonal antibody to the NH2-terminal myristoyl-Gly-Ser-Ser-Lys src-peptide.  [electronic resource] 

 -  Biochemical and biophysical research communications  Jul 1990 
 - 657-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0006-291X 
<br/><br/><label>Standard No.: </label>10.1016/0006-291x(90)92142-m  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--immunology<br/>Amino Acid Sequence<br/>Antibodies, Monoclonal--immunology<br/>Antibody Specificity<br/>Blotting, Western<br/>Colonic Neoplasms--immunology<br/>Humans<br/>Molecular Sequence Data<br/>Multiple Myeloma--immunology<br/>Myristic Acid<br/>Myristic Acids--metabolism<br/>Oligopeptides--immunology<br/>Oncogene Protein pp60(v-src)--immunology<br/>Pancreatic Neoplasms--immunology<br/>Peptides--immunology<br/>Precipitin Tests<br/>Tumor Cells, Cultured